Business Insider
My Markets Watchlist
Markets Stocks

Johnson & Johnson Stock , JNJ

156.67 +1.38 +0.89%
03:59:59 PM BTT
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Thursday 06/12/2025 the closing price of the Johnson & Johnson share was $156.67 on BTT. Compared to the opening price on Thursday 06/12/2025 on BTT of $156.14, this is a gain of 0.34%. Johnson & Johnson's market capitalization is $305.20 B by 2.41 B shares outstanding.
Is Johnson & Johnson stock a Buy, Sell or Hold? Johnson & Johnson stock has received a consensus rating of buy. The average rating score is Aaa and is based on 51 buy ratings, 27 hold ratings, and 1 sell ratings.
What was the 52-week low for Johnson & Johnson stock? The low in the last 52 weeks of Johnson & Johnson stock was 140.68. According to the current price, Johnson & Johnson is 111.36% away from the 52-week low.
What was the 52-week high for Johnson & Johnson stock? The high in the last 52 weeks of Johnson & Johnson stock was 170.00. According to the current price, Johnson & Johnson is 92.16% away from the 52-week high.
What are analysts forecasts for Johnson & Johnson stock? The 79 analysts offering price forecasts for Johnson & Johnson have a median target of 184.43, with a high estimate of 215.00 and a low estimate of 150.00. The median estimate represents a 84.95 difference from the last price of 156.67.

Johnson Johnson Stock Snapshot

155.86
Bid
1.00
Bid Size
156.73
Ask
50.00
Ask Size
6/12/2025
Date
3:59 PM
Time
275,047.00
Volume
155.29
Prev. Close
156.14
Open
373.73 B
Market Cap in USD
2.41 B
Number of Shares
2.41 B
Total Number of Shares
155.17
Day Low
156.67
Day High
156.67
140.68
52 Week Low
170.00
52 Week High
156.67
4.91
Dividend in USD
3.40
Dividend Yield
24.98
P/E Ratio
99.86
Free Float in %
5.79
EPS in USD
29.70
Book Value per Share in USD
9.99
Cash Flow per Share in USD

Historical Prices for Johnson & Johnson

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Johnson & Johnson Analyst Data

Total Analysts: 79
Buy Ratings: 51 Neutral Ratings: 27 Sell Ratings: 1
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 150.00 Median: 184.43 Highest: 215.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Johnson & Johnson Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
06/05/25 RBC Capital Markets
Maintained Buy $181
04/17/25 Barclays Capital
Maintained Hold $165
04/16/25 Morgan Stanley
Maintained Hold $169
04/16/25 RBC Capital Markets
Maintained Buy $181
04/14/25 Raymond James Financial, Inc.
Maintained Buy $162
04/10/25 Bank of America Merrill Lynch
Maintained Hold $159
04/09/25 Morgan Stanley
Maintained Hold $164
04/09/25 Goldman Sachs
Upgraded to Buy $172
04/02/25 RBC Capital Markets
Maintained Buy $181
04/02/25 Guggenheim
Maintained Hold
03/10/25 Guggenheim
Maintained Hold
03/05/25 Bank of America Merrill Lynch
Maintained Hold $171
02/19/25 RBC Capital Markets
Maintained Buy $181
02/03/25 Guggenheim
Maintained Hold $166
01/28/25 Barclays Capital
Maintained Hold $166
01/23/25 RBC Capital Markets
Maintained Buy $181
01/23/25 Morgan Stanley
Maintained Hold $163
01/23/25 Stifel, Nicolaus & Co., Inc.
Maintained Buy $155
01/23/25 Wells Fargo & Co
Maintained Hold $152
01/23/25 Raymond James Financial, Inc.
Maintained Buy $165
01/23/25 Bank of America Merrill Lynch
Maintained Hold $159
07/30/24 Cantor Fitzgerald
Maintained Buy $215
07/30/24 RBC Capital Markets
Maintained Buy $175
07/23/24 Daiwa Securities
Downgraded to Hold $150
07/19/24 Goldman Sachs
Maintained Hold $155
07/18/24 RBC Capital Markets
Maintained Buy $175
07/18/24 Morgan Stanley
Maintained Hold $169
07/01/24 Cantor Fitzgerald
Maintained Buy $215
06/25/24 Cantor Fitzgerald
Maintained Buy $215
06/20/24 Cantor Fitzgerald
Maintained Buy $215
06/17/24 RBC Capital Markets
Maintained Buy $175
06/04/24 RBC Capital Markets
Maintained Buy $175
05/22/24 RBC Capital Markets
Maintained Buy $175
05/16/24 RBC Capital Markets
Maintained Buy $175
05/06/24 Cantor Fitzgerald
Maintained Buy $215
04/18/24 HSBC
Upgraded to Buy $170
04/17/24 RBC Capital Markets
Maintained Buy $175
04/17/24 Bank of America Merrill Lynch
Maintained Hold $170
04/15/24 Cantor Fitzgerald
Maintained Buy $215
03/13/24 Cantor Fitzgerald
Maintained Buy $215
02/28/24 RBC Capital Markets
Maintained Buy $181
02/20/24 Cantor Fitzgerald
Maintained Buy $215
02/06/24 Cantor Fitzgerald
Maintained Buy $215
01/24/24 Morgan Stanley
Maintained Hold $169
01/24/24 RBC Capital Markets
Maintained Buy $181
01/23/24 Cantor Fitzgerald
Maintained Buy $215
01/09/24 Cantor Fitzgerald
Maintained Buy $215
01/03/24 Raymond James Financial, Inc.
Maintained Buy $175
12/13/23 Wells Fargo & Co
Downgraded to Hold $163
12/06/23 RBC Capital Markets
Maintained Buy $181

Johnson & Johnson Estimates* in USD

  2025 2026 2027 2028 2029
Revenue 91,303 95,124 99,430 103,173 109,497
Dividend 5.14 5.21 5.45 5.75 -
Dividend Yield (in %) 3.31 % 3.35 % 3.51 % 3.70 % 4.22 %
EPS 10.61 11.10 11.85 12.56 13.57
P/E Ratio 14.63 13.99 13.10 12.36 11.45
EBIT 29,735 31,383 33,371 34,651 37,463
EBITDA 34,291 35,639 37,926 39,686 39,185
Net Profit 25,715 26,476 28,291 30,036 32,022
Net Profit Adjusted 25,610 26,685 28,686 30,036 32,022
Pre-Tax Profit 30,730 32,164 34,543 36,092 38,571
Pre-Tax Profit Reported 29,202 29,119 33,136 - -
EPS (Non-GAAP) ex. SOE - - - 13.47 -
EPS (GAAP) 10.95 10.35 11.55 - -
Gross Income 66,017 69,265 72,046 77,179 81,717
Cash Flow from Investing -6,686 -6,791 -6,921 - -
Cash Flow from Operations 23,991 24,350 25,111 - -
Cash Flow from Financing -24,710 -26,178 -16,756 - -
Cash Flow per Share 12.71 12.57 13.86 - -
Free Cash Flow 26,090 23,644 24,537 30,376 -
Free Cash Flow per Share 6.04 5.98 5.06 - -
Book Value per Share 31.26 34.96 39.65 - -
Net Debt 5,376 -5,442 -17,955 -33,216 -
Research & Development Exp. 14,629 15,260 15,705 16,151 16,857
Capital Expenditure 4,231 4,364 4,504 5,242 -
Selling, General & Admin. Exp. 22,050 22,830 23,743 24,762 25,909
Shareholder’s Equity 70,425 66,152 72,304 - -
Total Assets 172,417 164,385 168,203 - -
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 12/31/25 		Next Year
ending 12/31/26
Earnings Estimates
No. of Analysts - 16 16 20 19
Average Estimate - 2.678 USD 2.684 USD 10.612 USD 11.102 USD
Year Ago - 1.947 USD 1.119 USD 5.843 USD -
Publish Date - 7/16/2025 10/21/2025 - -
Revenue Estimates
No. of Analysts - - - 18 17
Average Estimate - - - 91,303 USD 95,124 USD
Year Ago - - - 88,819 USD -
Publish Date - - - - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Sales 88,819.00 85,152.00 95,015.00 93,758.00 82,572.00 82,113.00 81,534.00
Change of sales in % 4.31 -10.38 1.34 13.55 0.56 0.71 6.61
Gross profit on sales 60,957.00 58,722.00 64,297.00 63,884.00 54,574.00 54,978.00 54,348.00
Gross profit on sales change in % 3.81 -8.67 0.65 17.06 -0.73 1.16 5.79
Operating income 20,823.00 22,162.00 24,780.00 24,481.00 20,468.00 21,550.00 21,253.00
Operating income change in % -6.04 -10.56 1.22 19.61 -5.02 1.40 8.63
Income before tax 16,687.00 15,062.00 21,725.00 22,776.00 16,497.00 17,328.00 17,999.00
Income before tax change in % 10.79 -30.67 -4.61 38.06 -4.80 -3.73 1.84
Income after tax 14,066.00 13,326.00 17,941.00 20,878.00 14,714.00 15,119.00 15,297.00
Income after tax change in % 5.55 -25.72 -14.07 41.89 -2.68 -1.16 1,076.69

Balance Sheet in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Total liabilities 108,614.00 98,784.00 110,574.00 107,995.00 111,616.00 98,257.00 93,202.00
Long-term liabilities per share 24.22 21.81 20.96 23.88 26.26 23.66 23.28
Equity 71,490.00 68,774.00 76,804.00 74,023.00 63,278.00 59,471.00 59,752.00
Equity change in % 3.95 -10.46 3.76 16.98 6.40 -0.47 -0.68
Balance sheet total 180,104.00 167,558.00 187,378.00 182,018.00 174,894.00 157,728.00 152,954.00
Balance sheet total change in % 7.49 -10.58 2.94 4.07 10.88 3.12 -2.76

Key Data in USD

2024 2023 2022 2021 2020 2019 2018
Sales per share 36.56 33.26 35.67 35.06 30.92 30.59 29.88
P/E ratio (year end quote, basic EPS) 24.98 28.32 26.23 21.91 28.57 25.88 22.69
P/E ratio (year end quote, diluted EPS) 24.98 28.32 26.23 21.91 28.57 25.88 22.69
Dividend yield in % 3.40 3.00 2.52 2.45 2.53 2.57 2.78
Equity ratio in % 39.69 41.04 40.99 40.67 36.18 37.70 39.07
Debt ratio in % 60.31 58.96 59.01 59.33 63.82 62.30 60.93

Johnson & Johnson Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
REED JOHN C 04/30/2025 11,002.00 29,795.00 156.31 Sell No
REED JOHN C 04/30/2025 25,255.00 40,797.00 n/a Buy No
Duato Joaquin 03/17/2025 130,852.00 275,967.00 n/a Sell No
Duato Joaquin 03/17/2025 130,852.00 130,852.00 n/a Buy No
Decker Robert J 02/24/2025 6,999.00 21,001.00 165.88 Sell No
Decker Robert J 02/24/2025 6,999.00 28,000.00 101.87 Buy No
Duato Joaquin 02/17/2025 1,602.00 395,923.00 156.15 Sell No
Taubert Jennifer L 02/17/2025 651.00 170,459.00 156.15 Sell No
Wengel Kathryn E 02/17/2025 200.00 90,836.87 156.15 Sell No
Mulholland Kristen 02/17/2025 120.00 12,975.00 156.15 Sell No
Swanson James D. 02/17/2025 141.00 16,620.59 156.15 Sell No
Wolk Joseph J 02/17/2025 768.00 5,345.00 156.15 Sell No
REED JOHN C 02/17/2025 385.00 15,542.00 156.15 Sell No
Schmid Timothy 02/17/2025 403.00 15,098.00 156.15 Sell No
Decker Robert J 02/17/2025 94.00 20,022.00 156.15 Sell No
Forminard Elizabeth 02/17/2025 307.00 10,014.00 156.15 Sell No
Broadhurst Vanessa 02/17/2025 158.00 21,681.00 156.15 Sell No
Duato Joaquin 02/14/2025 3,682.00 397,525.00 n/a Buy No
Taubert Jennifer L 02/14/2025 1,594.00 171,110.00 n/a Buy No
Wengel Kathryn E 02/14/2025 607.00 91,036.87 n/a Buy No
Mulholland Kristen 02/14/2025 419.00 13,095.00 n/a Buy No
Swanson James D. 02/14/2025 492.00 16,761.59 n/a Buy No
Wolk Joseph J 02/14/2025 1,971.00 6,113.00 n/a Buy No
REED JOHN C 02/14/2025 1,350.00 15,927.00 n/a Buy No
Schmid Timothy 02/14/2025 1,029.00 15,501.00 n/a Buy No

Johnson Johnson Dividend Calendar

Date Name Dividend *yield Currency
2024 Johnson & Johnson 4.91 3.40 USD
2023 Johnson & Johnson 4.70 3.00 USD
2022 Johnson & Johnson 4.45 2.52 USD
2021 Johnson & Johnson 4.19 2.45 USD
2020 Johnson & Johnson 3.98 2.53 USD
2019 Johnson & Johnson 3.75 2.57 USD
2018 Johnson & Johnson 3.54 2.78 USD
2017 Johnson & Johnson 3.32 2.38 USD
2016 Johnson & Johnson 3.15 2.73 USD
2015 Johnson & Johnson 2.95 2.87 USD
2014 Johnson & Johnson 2.76 2.63 USD
2013 Johnson & Johnson 2.59 2.80 USD
2012 Johnson & Johnson 2.40 3.45 USD
2011 Johnson & Johnson 2.25 3.43 USD
2010 Johnson & Johnson 2.11 3.41 USD
2009 Johnson & Johnson 1.93 3.00 USD
2008 Johnson & Johnson 1.79 3.06 USD
2007 Johnson & Johnson 1.62 2.43 USD
2006 Johnson & Johnson 1.46 2.21 USD
2005 Johnson & Johnson 1.27 2.11 USD
2004 Johnson & Johnson 1.09 1.72 USD
2003 Johnson & Johnson 0.92 1.82 USD
2002 Johnson & Johnson 0.79 1.47 USD
2001 Johnson & Johnson 0.70 1.17 USD
2000 Johnson & Johnson 0.62 1.18 USD
1999 Johnson & Johnson 0.55 1.18 USD
*Yield of the Respective Date

Johnson Johnson Calendar

Event Estimate Info Date
Earnings Report 2.678 USD Q2 2025 Earnings Release 07/16/2025
Earnings Report 2.684 USD Q3 2025 Earnings Release 10/21/2025
Earnings Report 2.487 USD Q4 2025 Earnings Release 01/27/2026
Earnings Report 2.693 USD Q1 2026 Earnings Release 04/21/2026
Earnings Report 2.788 USD Q2 2026 Earnings Release 07/22/2026

Johnson Johnson Past Events

Event Actual EPS Info Date
Annual General Meeting 5.790 USD Annual General Meeting 04/24/2025
Earnings Report 4.540 USD Q1 2025 Earnings Release 04/15/2025
Earnings Report 1.410 USD Q4 2024 Earnings Release 01/22/2025
Earnings Report 1.110 USD Q3 2024 Earnings Release 10/15/2024
Earnings Report 1.930 USD Q2 2024 Earnings Release 07/17/2024
Annual General Meeting 13.720 USD Annual General Meeting 04/25/2024
Earnings Report 1.340 USD Q1 2024 Earnings Release 04/16/2024
Earnings Report 1.670 USD Q4 2023 Earnings Release 01/23/2024
Earnings Report 1.690 USD Q3 2023 Earnings Release 10/17/2023
Earnings Report 1.960 USD Q2 2023 Earnings Release 07/20/2023
Annual General Meeting 6.730 USD Annual General Meeting 04/27/2023
Earnings Report -0.030 USD Q1 2023 Earnings Release 04/18/2023
Earnings Report 1.330 USD Q4 2022 Earnings Release 01/24/2023
Earnings Report 1.680 USD Q3 2022 Earnings Release 10/18/2022
Earnings Report 1.800 USD Q2 2022 Earnings Release 07/19/2022
Annual General Meeting 7.810 USD Annual General Meeting 04/28/2022
Earnings Report 1.930 USD Q1 2022 Earnings Release 04/19/2022
Earnings Report 1.770 USD Q4 2021 Earnings Release 01/25/2022

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
1
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Johnson & Johnson Management

Name Job
Joaquin Duato Chairman & Chief Executive Officer
Ronald A. Kapusta Chief Accounting Officer & Controller
Robert J. Decker Chief Accounting Officer & Controller
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Kristen Blair Mulholland Chief Human Resources Officer & Executive VP
James D. Swanson Chief Information Officer & Executive VP
Elizabeth Forminard Chief Legal Officer & Executive Vice President
Penny M. Heaton Chief Medical Officer
Kathryn E. Wengel Chief Technical Operations & Risk Officer
George Davy Director-Global Human Resources
Jonathan Sheh Director-Workplace Experience
Jennifer L. Taubert EVP & Worldwide Chairman-Innovative Medicine
Timothy Schmid Executive Vice President & Chairman-Worldwide
John C. Reed Executive Vice President-Innovative Medicine
Michael Bzdak Global Dir-Employee Engagement-Global Cmnty Impact
Jessica Moore Group Chief Financial Officer-Innovative Medicine
Juliana Clawson Head-Global Quality & Compliance
Paula A. Johnson Independent Director
Mary C. Beckerle Independent Director
Eugene A. Woods Independent Director
Nadja Y. West Independent Director
Jennifer A. Doudna Independent Director
Mark Alan Weinberger Independent Director
Anne M. Mulcahy Independent Director
Mark B. McClellan Independent Director
Hubert Joly Independent Director
Marillyn A. Hewson Lead Independent Director
Thomas J. Spellman Secretary
Marc Larkins Secretary & Vice President-Governance
Darren Snellgrove Vice President-Investor Relations